Houston, TX - April 7th, 2025 - OmniScience, the AI company behind Vivo - the first agentic AI control tower for clinical trials - announced today that it has successfully passed the rigorous Expert Sift™ process and has advanced to the due diligence stage with Astia, a global investment organization committed to funding high-growth companies with women in leadership.

Astia’s unique model for investment includes a multi-stage screening process led by its global community of more than 6,000 domain experts, investors, and operational leaders. Fewer than 5% of companies entering Astia’s pipeline progress to the due diligence stage, making OmniScience’s advancement noteworthy

“We’re honored to be recognized by Astia’s investor network and excited to enter the next phase of partnership,” said Angela Holmes, CEO and Co-Founder of OmniScience. “As a woman-led company on a mission to transform clinical development with AI, it’s meaningful to align with an organization equally committed to amplifying high-impact innovation and diverse leadership.”

OmniScience is pioneering agentic AI in clinical development with Vivo, its flagship platform that enables trial teams to unify fragmented data, generate real-time insights, and accelerate decision-making. Vivo reduces trial timelines, reduces cost, and increases the probability of success - all while maintaining regulatory-grade auditability.

This milestone validates both OmniScience’s market potential and its leadership’s vision to reimagine clinical development with the next generation of AI. Advancing to due diligence with Astia is a critical step in the company’s continued growth and commitment to delivering powerful, equitable innovation in life sciences.